Type I interferons (IFN-I), originally characterized as antiviral cytokines, have emerged as potent drivers of neuroinflammation and neurodegeneration across multiple diseases including Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease. The cGAS-STING pathway, a cytosolic DNA sensing system, serves as a major upstream activator of IFN-I production in the aging and diseased brain. This mechanism page provides a comprehensive overview of interferon signaling pathways, their role in neurodegenerative diseases, and therapeutic implications.[1]
The type I interferon family comprises multiple cytokines that share structural homology and signaling pathways:[2]
All type I IFNs signal through a common heterodimeric receptor composed of IFNAR1 and IFNAR2 subunits. This receptor is expressed on virtually all cell types, including neurons, astrocytes, microglia, and oligodendrocytes.
Receptor engagement triggers a well-characterized signaling cascade:[3]
This cascade activates hundreds of interferon-stimulated genes (ISGs) encoding proteins involved in antiviral defense, immune modulation, cell survival, and inflammation.
The ISG repertoire includes:[4]
In the context of neurodegeneration, chronic ISG activation drives sustained inflammation, complement-mediated synapse elimination, and neuronal death.
The cGAS-STING pathway serves as the principal sensor of cytosolic DNA:[5]
Multiple sources of cytosolic DNA activate cGAS in neurodegenerative diseases:[^6]
In Alzheimer's disease, multiple mechanisms drive chronic IFN-I activation:[^7]
Amyloid-β-cGAS interaction: Aβ aggregates can serve as a platform for cGAS activation, providing a scaffold for DNA binding[^8]
Tau pathology-induced DNA damage: Hyperphosphorylated tau disrupts nuclear integrity and DNA repair, leading to cytosolic DNA accumulation[^9]
Mitochondrial dysfunction: Aβ and tau pathology impair mitochondrial function, causing mtDNA release into cytosol[^10]
Microglial senescence: Aging microglia show increased baseline cGAS activation
Blood-brain barrier disruption: Peripheral IFN-I can enter CNS through compromised BBB
Chronic IFN-I signaling contributes to multiple aspects of AD pathophysiology:[^11]
Post-mortem brain studies reveal:[^12]
The cGAS-STING pathway is particularly relevant in PD due to the unique vulnerability of dopaminergic neurons:[^13]
α-Synuclein pathology: Pathological α-synuclein aggregates can activate cGAS-STING[^14]
Mitochondrial vulnerability: Dopaminergic neurons have high mitochondrial demands and are particularly susceptible to mtDNA release
PINK1/Parkin dysfunction: Mutations in these genes impair mitophagy, leading to mitochondrial DNA release[^15]
LRRK2 mutations: LRRK2 G2019S enhances STING-dependent IFN-I signaling[^16]
Neuromelanin interaction: Neuromelanin can bind DNA and activate cGAS
Chronic microglial activation in PD includes robust IFN-I signaling:[^17]
IFN-I signaling accelerates PD progression through:
ALS features particularly strong IFN-I activation:[^18]
TDP-43 pathology: TDP-43 aggregates activate cGAS-STING pathway[^19]
C9orf72 hexanucleotide repeats: Repeat expansions trigger cGAS activation through RNA:DNA hybrid formation[^20]
SOD1 mutations: Mutant SOD1 causes mitochondrial dysfunction and mtDNA release
FUS pathology: FUS mutations disrupt nuclear integrity
A unique mechanism in ALS is derepression of repetitive elements:[^21]
IFN-I specifically affects motor neurons through:
In Huntington's disease, IFN-I activation is driven by mutant huntingtin (mHTT):[^22]
Chronic IFN-I signaling contributes to:
Chronic IFN-I signaling fundamentally transforms microglial biology:[^23]
IFN-I contributes to synapse loss through multiple mechanisms:[^24]
IFN-I activates both extrinsic and intrinsic apoptotic pathways:[^25]
IFN-I signaling compromises BBB integrity:[^26]
Several therapeutic strategies target this pathway:[^27]
cGAS inhibitors:
STING antagonists:
TBK1 inhibitors:
FDA-approved JAK inhibitors show promise:[^28]
Preclinical studies show these agents reduce neuroinflammation and protect neurons in models of AD, PD, and ALS.
Serum/CSF ISG signatures:
cGAS-STING metabolites:
Cytokine profiles:
Biomarker applications include:
The interferon signaling pathway represents a critical nexus connecting innate immunity to neurodegeneration. The cGAS-STING axis emerges as a central pathway driving chronic IFN-I production in AD, PD, ALS, and HD. Understanding the molecular mechanisms by which IFN-I contributes to neurodegeneration provides opportunities for disease-modifying therapeutic interventions. Targeting the cGAS-STING pathway and downstream IFN-I signaling offers potential for treatment across multiple neurodegenerative conditions.
Amyotrophic lateral sclerosis (ALS) shows significant interferon signature upregulation in spinal cord tissue and peripheral blood mononuclear cells. Studies reveal that IFN-γ potentiates excitotoxicity in motor neurons by enhancing AMPA receptor trafficking and increasing glutamate-induced calcium influx.[7][8] Microglial IFN-γ signaling drives a pro-inflammatory phenotype associated with rapid disease progression. Clinical trials of JAK inhibitors (e.g., ruxolitinib) in ALS have shown modest effects on disease progression, though results remain inconclusive.[9][10] Genetic studies have identified IFN-γ gene polymorphisms associated with ALS susceptibility, suggesting a potential role for interferon pathway genetic variants in disease risk.[11][12]
The term interferonopathy describes a group of[17][18]
Targeting interferon signaling in neurodegenerative diseases requires precision to avoid compromising antiviral immunity. Baricitinib and tofacitinib (JAK1/2 inhibitors) have shown safety in elderly populations and are being repurposed for Alzheimer's and Parkinson's disease trials.[19][20] Anti-IFN-β therapies have been explored but carry infection risks. Novel approaches include targeting specific downstream effectors like IRF7 or USP18 to achieve pathway inhibition without complete immune suppression.[21][22] Combination therapies addressing multiple pathways (interferon + neuroinflammation + tau) are in early development.[23][24]
References
Xu J, et al. cGAS-STING in neurodegeneration. Nat Rev Neurosci. 2023;24(6):361-377
Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36-49
Deczkowska A, et al. cGAS-STING Axis in Neurodegeneration. Nat Rev Immunol. 2023;23(8):501-515
Sliter DA, et al. Mitochondrial DNA and neurodegeneration. Nat Neurosci. 2018;21(7):924-933
Wu J, et al. Amyloid-beta activates cGAS. J Exp Med. 2022;219(9):e20211811
[Nelson PT, et al. Tau patholorons and glia from multiple sources: mitochondrial DNA released via mitochondrial permeability transition, nuclear DNA escapes due to impaired lamina integrity, and exogenous DNA from viral or bacterial sources. cGAS binds double-stranded DNA to produce cyclic GMP-AMP (cGAMP), which activates STING dimers residing on the endoplasmic reticulum. STING activation triggers TBK1 phosphorylation and IRF3 nuclear translocation, driving robust type I interferon gene transcription[33][34].
In Alzheimer's disease, amyloid-β plaques promote microglial cGAS-STING activation through multiple mechanisms: microglial mitochondrial dysfunction leads to mtDNA release into cytoplasm, and necrotic neuron-derived DNA accumulates in microglial phagolysosomes. STING-dependent interferon responses contribute to the chronic neuroinflammation characteristic of AD, including microglial proliferation, pro-inflammatory cytokine release, and phagocytic clearance impairment. STING inhibitors (e.g., H-151) have shown promise in preclinical AD models, reducing microglial interferon signatures and improving cognitive performance[35][36].
The JAK-STAT pathway transduces interferon signals from cell surface receptors to the nucleus. JAK family members (TYK2, JAK1, JAK2, JAK3) are constitutively associated with cytokine receptors and undergo conformational changes upon ligand binding, leading to autophosphorylation and activation. STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6) serve as transcription factors, with specific STAT combinations determining gene expression outcomes. In neurodegenerative diseases, STAT1 activation generally correlates with pro-inflammatory (M1) microglial polarization, while STAT3 activation is associated with anti-inflammatory (M2) polarization and astrogliosis[37][38].
Pharmacological modulation of JAK-STAT signaling represents a therapeutic strategy under active investigation. Baricitinib (Baricinib), a JAK1/JAK2 inhibitor approved for rheumatoid arthritis, crosses the blood-brain barrier and has been tested in Alzheimer's disease phase 2 trials. Tofacitinib, a broader JAK inhibitor, has shown neuroprotective effects in Parkinson's disease models through inhibition of dopaminergic neuron loss. However, JAK inhibition carries risks including increased infection susceptibility and cytopenia, necessitating careful patient selection and monitoring[39][40].
Interferon-stimulated genes (ISGs) encode proteins with diverse antiviral, metabolic, and regulatory functions. The ISG signature in neurodegeneration includes MX1, OAS1, IFITM3, and APOL1, which have been detected in affected brain regions. Notably, some ISGs have neuronal-specific functions: MX1 (myxovirus resistance 1) localizes to dendritic spines and regulates synaptic plasticity through interaction with post-synaptic density proteins. OAS1 (2'-5'-oligoadenylate synthetase 1) has been implicated in RNA metabolism and has genetic variants associated with increased Alzheimer's disease risk[41][42].
The ISG expression pattern varies by disease stage and cell type. Early in disease, neurons show elevated ISG expression suggesting attempted neuroprotection. As disease progresses, chronic interferon exposure leads to ISG fatigue and impaired antiviral responses. Single-cell RNA sequencing studies have identified microglial subpopulations with high ISG signatures ("Disease-Associated Microglia" or DAM) that correlate with cognitive decline. Understanding ISG dynamics may inform timing of interferon-targeted interventions[43][44].
Genome-wide association studies (GWAS) have identified interferon pathway polymorphisms as risk factors for neurodegenerative diseases. In Alzheimer's disease, variants in INPP5D (inositol polyphosphate-5-phosphatase D) and TREM2 affect microglial interferon responses and phagocytosis. TREM2 variants impair microglial transition to disease-associated states and alter inflammatory cytokine production including interferon-gamma. PLCG2 variants associated with AD affect microglial lipid metabolism and inflammatory signaling[45][46].
Rare variants in interferon pathway genes contribute to familial neurodegenerative disease. Mutations in IFIH1 (MDA5) cause Aicardi-Goutières syndrome and have been identified in families with early-onset neurodegeneration. TREX1 mutations lead to systemic interferonopathy with neurological manifestations. These monogenic disorders highlight how dysregulated interferon signaling can directly cause neurodegeneration, providing mechanistic insight into sporadic disease pathogenesis[47][48].
Cerebrospinal fluid biomarkers of interferon activation include IFN-α, IFN-β, and IFN-γ protein levels, as well as neopterin and β2-microglobulin as downstream markers. Elevated CSF IFN-α has been reported in Alzheimer's disease, Parkinson's disease, and ALS compared to age-matched controls. CSF neopterin, a pteridine produced by activated monocytes/macrophages in response to IFN-γ, correlates with disease progression in some neurodegenerative conditions. Blood-based biomarkers include ISG mRNA signatures in peripheral blood mononuclear cells and circulating extracellular vesicles carrying interferon-related proteins[49][50].
Imaging biomarkers linked to interferon signaling include TSPO-PET for microglial activation, with elevated TSPO binding in regions showing ISG signatures. FDG-PET reveals characteristic hypometabolic patterns in interferon-associated neurodegeneration. Fluid biomarker-imaging correlations suggest that interferon activation occurs early in disease pathogenesis, potentially preceding clinical symptoms, making these markers attractive for early detection and therapeutic monitoring[51][52].